focus -WSS

focus

author：comprehensive 2025-09-02 11:35:59 - browse：1

Black and white illustrated portrait of Mark Parrino — Mark Parrino: "I don’t think the dominant interest is just giving lots more take-homes to patients. There’s more to treatment than that." Molly Ferguson for STAT

Nobody has made more of an impact on methadone treatment than Mark Parrino.

For decades, he’s served as the founder and president of the American Association for the Treatment of Opioid Dependence, a nationwide advocacy group representing methadone clinics. Before AATOD, he ran a statewide advocacy group in New York, having made the jump to politics and policy after working as a clinic director and, before that, as an addiction counselor.

Now, a half-century after he began his career in addiction treatment, Parrino is facing what is perhaps a career-defining fight. In the last few years alone, the nation’s tone on opioid treatment programs (OTPs), as they are known, has shifted significantly. While methadone has long been stigmatized, a growing coalition of advocates, lawmakers, and addiction doctors is now pushing to significantly deregulate methadone treatment — and in particular, to offer it outside the context of the specialized clinics that Parrino has long represented.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

BMI, flaws aside, is found to be useful estimate of body fat in youth

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Keeping primary care docs in field isn't impossible, says AAFP CEO

What STAT readers think about the FDA and patient advocacy

knowledge

focus

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Violet CEO on training clinicians to promote more inclusive care

Apple is now the first public company to be valued at $3 trillion

How to keep neuroscience’s past racism from being its future

The high cost of giving birth even with insurance

Ultragenyx gene therapy for rare liver ailment succeeds in late

Anesthesiologist group: stop taking Ozempic before surgery

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage beneficiaries sue Humana over algorithm use

hotspot

Prime Medicine, Myeloid Therapeutics clash over genome

Why health care costs have stayed mostly flat since 2010

Let's speed up science by embracing open access publishing

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Let's speed up science by embracing open access publishing

Grail spinoff by Illumina should end disastrous merger attempt

hotspot

focus

Wikipedia

explore